DESCRIPTION

• Notes: Visit bpsbioscience.com/assay-kits-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com
• Species: SARS-CoV-2
• Shiptemp: -80°C (dry ice)
• Synonyms: coronavirus, covid, covid-19, covid19, Sars-cov-2 B.1.351, sars cov 2, sarscov2, S.Africa variant, SA mutation assay kit, 501Y.V2 kit, South African variant inhibitor screening, B1351 assay, chemiluminescent Spike RBD kit, B.1.351 inhibitor kit
• Warnings: Avoid freeze/thaw cycles of frozen components.
• Category: Coronavirus/Assay Kit
• Background: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Receptor Binding Domain (RBD) of Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. It has been widely suggested that active as well as passive immunizations targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 offer promising protection against the viral infection. A variant strain of SARS-COV-2, identified as B.1.351, was first identified in the fall of 2020 in the Republic of South Africa. This South African variant, also known as 501Y.V2, has many mutations which may lead to higher transmissibility and infectivity. In particular, the B.1.351 variant contains three mutations within the RBD region of the Spike S1 protein: K417N, E484K, and N501Y. Investigating the effect of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19.
• References: 1. Wang P. et al., Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv 2021 Jan 26; 2021.01.25.4281372. Shen X., et al., SARS-CoV-2 Variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv. 2021 Jan 29; 2021.01.27.4285163. Hoffman M. et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020; 181:1-10
• Description: The Spike S1 RBD-B.1.351 (SARS-CoV-2): ACE2 Inhibitor Screening Chemiluminescence Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the RBD region of the B.1.351 variant of the SARS-CoV-2 Spike S1 protein.
• Methodology: Chemiluminescent
• Supplied As: This kit comes in a convenient 96-well format, with purified Spike S1 RBD-B.1.351 (SARS-CoV-2) and ACE2-Biotin proteins, streptavidin-HRP, chemiluminescence HRP substrate, and assay buffer for 100 binding reactions.
• Unspsc Code: 41105332
• Unspsc Name: Protein chemiluminescent detection reagents or kits or substrates
• Applications: This kit is useful for screening inhibitors of ACE2 binding to Spike S1 RBD-B.1.351 (SARS-CoV-2).
• Product Type: Assay Kit
• Biosafety Level: Not applicable (BSL-1)
• Related Products: 78133, 78140, 78142, 78152
• Storage Stability: Upon arrival, store individual kit components at the recommended temperatures. This assay kit will perform optimally for up to 6 months from date of receipt when the materials are stored as directed.
• Scientific Category: Coronavirus
• Instructions for Use: See assay protocol for detailed instructions.